Please assess the completion status of the following clinical trial:

Trial Title: Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of 1 of the following:~  * B-cell non-Hodgkin's lymphoma (NHL)~ * Hodgkin's lymphoma~ * Post-transplant lymphoproliferative disorder (PTLD)~ * Lymphoblastic leukemia~* CD20-positive disease verified by immunophenotyping at original diagnosis, disease relapse, or disease progression~* Refractory to conventional therapy, defined as 1 of the following:~  * Medically refractory HIV-associated NHL~ * Refractory or recurrent lymphoblastic leukemia~ * PTLD~ * In \> first relapse or progression of B-cell NHL or Hodgkin's lymphoma~* Measurable (CT scan or MRI) or evaluable (marrow metastases or circulating lymphoblasts) disease within 4 weeks after completion of prior systemic (including systemic steroids) therapy~PATIENT CHARACTERISTICS:~Age~* Under 22~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count \> 500/mm\^3\*~* Platelet count \> 10,000/mm\^3\* NOTE: \*Excluding patients with PTLD or CD20-positive lymphoblastic leukemia~Hepatic~* Hepatic toxicity ≤ grade 2~Renal~* Creatinine clearance ≥ 60 mL/min~* Renal toxicity ≤ grade 2~Cardiovascular~* Cardiac toxicity ≤ grade 2~Pulmonary~* Pulmonary toxicity ≤ grade 2~Immunologic~* Human anti-mouse antibody (HAMA) ≤ 1,000 units/mL~* Human anti-chimeric antibody titer negative~* No active, life-threatening infections except Epstein-Barr virus-associated lymphoproliferative disorder~* No history of allergy to mouse proteins~* No history of allergy to rituximab or other chimeric monoclonal antibodies~* No history of allergy to beta-glucan or oats, barley, mushrooms, or yeast~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Grade 3 hearing deficit allowed~* Gastrointestinal toxicity ≤ grade 2~* Neurologic toxicity ≤ grade 2~* No severe major organ toxicity~PRIOR CONCURRENT THERAPY:~Biologic therapy~* See Disease Characteristics~* More than 4 weeks since prior rituximab~* No prior mouse antibodies~* No prior chimeric antibodies~Chemotherapy~* Not specified~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Group I (Type: EXPERIMENTAL): Patients receive rituximab IV on days 1, 8, 15, and 22 and oral beta-glucan once daily on days 1-28 (days 8-28 of course 1). Treatment repeats every 42 days for 4 courses.
- Group II (Type: EXPERIMENTAL): Patients receive rituximab IV on days 1, 4, 8, 15, and 22 and oral beta-glucan once daily on days 8-28. Beginning on day 42, patients with responding disease may receive monthly rituximab prophylaxis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues